Next week marks the first anniversary of CAMP4 Therapeutics Corp. (CAMP) as a publicly listed company. Since its IPO, the stock has experienced a significant decline and trades around $2 per share, well below its initial offering price of $11.
CAMP4 is a clinical-stage biopharmaceutical company pioneering the development of antisense oligonucleotide (ASO) therapies that target regulatory RNA (regRNA) to boost gene expression and restore normal protein levels in metabolic and central nervous system (CNS) disorders, where key proteins are often underexpressed. Its lead drug candidate is CMP-CPS-001, being developed for the treatment of Urea Cycle Disorders.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.